Type to search

Kesimpta® (Ofatumumab) Data Show Long-term Preservation of IgG/IgM Levels and no Increased Risk of Serious Infections in People Living with Multiple Sclerosis | Pharmtech Focus
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial | Pharmtech Focus
New Roche Data for Evrysdi Show Improved Motor Function in Pre-symptomatic Babies after One Year and Confirm Safety Profile in Previously Treated People with Spinal Muscular Atrophy (SMA) | Pharmtech Focus